Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin E Ferner

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
Clinical Toxicology (Philadelphia, Pa.)|July 7, 2017
The toxicological significance of post-mortem drug concentrations in bileRobin E Ferner, Jeffrey K Aronson
British Journal of Clinical Pharmacology|August 17, 2022
Medicines legislation and regulation in the United Kingdom 1500-2020Robin E Ferner, Jeffrey K Aronson
Drug Safety|October 22, 2010
An algorithm for integrating contraindications into electronic prescribing decision supportRobin E Ferner, Jamie J Coleman
British Journal of Clinical Pharmacology|June 30, 2015
The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactionsJeffrey K Aronson, Robin E Ferner
BMJ (Clinical Research Ed.)|April 3, 2015
A licence to cureJeffrey K Aronson, Robin E Ferner
Drug Safety|October 11, 2011
Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions: a systematic reviewSarah E McDowell, Robin E Ferner
BMJ (Clinical Research Ed.)|December 15, 2015
Authors' reply to Green and colleaguesRobin E Ferner, Nithya J Gogtay
British Journal of Clinical Pharmacology|August 6, 2017
Unlicensed and off-label uses of medicines: definitions and clarification of terminologyJeffrey K Aronson, Robin E Ferner
BMJ (Clinical Research Ed.)|May 19, 2016
How similar are biosimilars?Jeffrey K Aronson, Robin E Ferner
BMJ (Clinical Research Ed.)|December 17, 2020
Harms and the Xmas factorRobin E Ferner, Jeffrey K Aronson
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Clinical Toxicology (Philadelphia, Pa.)|July 7, 2017
The toxicological significance of post-mortem drug concentrations in bileRobin E Ferner, Jeffrey K Aronson
British Journal of Clinical Pharmacology|August 17, 2022
Medicines legislation and regulation in the United Kingdom 1500-2020Robin E Ferner, Jeffrey K Aronson
Drug Safety|October 22, 2010
An algorithm for integrating contraindications into electronic prescribing decision supportRobin E Ferner, Jamie J Coleman
British Journal of Clinical Pharmacology|June 30, 2015
The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactionsJeffrey K Aronson, Robin E Ferner
BMJ (Clinical Research Ed.)|April 3, 2015
A licence to cureJeffrey K Aronson, Robin E Ferner
Drug Safety|October 11, 2011
Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions: a systematic reviewSarah E McDowell, Robin E Ferner
BMJ (Clinical Research Ed.)|December 15, 2015
Authors' reply to Green and colleaguesRobin E Ferner, Nithya J Gogtay
British Journal of Clinical Pharmacology|August 6, 2017
Unlicensed and off-label uses of medicines: definitions and clarification of terminologyJeffrey K Aronson, Robin E Ferner
BMJ (Clinical Research Ed.)|May 19, 2016
How similar are biosimilars?Jeffrey K Aronson, Robin E Ferner
BMJ (Clinical Research Ed.)|December 17, 2020
Harms and the Xmas factorRobin E Ferner, Jeffrey K Aronson
Pageof 10